ValuEngine Downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) to Hold

ValuEngine cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a hold rating in a report released on Tuesday morning, ValuEngine reports.

Several other analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Deciphera Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, August 2nd. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 price objective on the stock in a research report on Monday, August 5th. Guggenheim raised their price objective on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a buy rating in a research report on Tuesday. Piper Jaffray Companies raised their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an overweight rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Finally, Deutsche Bank began coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 18th. They set a buy rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals has a consensus rating of Buy and an average target price of $47.90.

Deciphera Pharmaceuticals stock opened at $37.00 on Tuesday. The firm’s fifty day moving average price is $23.38 and its 200-day moving average price is $24.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The stock has a market cap of $1.41 billion, a P/E ratio of -13.12 and a beta of 2.34. Deciphera Pharmaceuticals has a fifty-two week low of $18.55 and a fifty-two week high of $42.99.



Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $20.00 million. On average, analysts predict that Deciphera Pharmaceuticals will post -4.29 earnings per share for the current year.

In related news, Director Michael Douglas Taylor sold 22,500 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $40.77, for a total transaction of $917,325.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Thomas Patrick Kelly sold 11,250 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 185,607 shares of company stock worth $7,536,409. 7.02% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP bought a new stake in Deciphera Pharmaceuticals during the fourth quarter valued at $4,337,000. Geode Capital Management LLC raised its holdings in shares of Deciphera Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock valued at $3,503,000 after purchasing an additional 27,157 shares during the period. Bank of America Corp DE raised its holdings in shares of Deciphera Pharmaceuticals by 1,506.1% during the fourth quarter. Bank of America Corp DE now owns 23,561 shares of the company’s stock valued at $494,000 after purchasing an additional 22,094 shares during the period. Norges Bank acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter valued at about $6,974,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock valued at $43,000 after purchasing an additional 1,831 shares during the period. 59.10% of the stock is currently owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: When can a hold rating present a buying opportunity?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.